MIRAMAR, Fla., Jan. 13, 2020 (GLOBE NEWSWIRE) -- G
Post# of 36567
(Total Views: 229)
Posted On: 01/13/2020 12:29:15 PM
MIRAMAR, Fla., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Joe Moscato, the company’s President & Chief Executive Officer conducted an interview with Mike Elliott of CEO Roadshow, which is available at:
• http://ceoroadshow.com/ceoroadshow-interview-...logy-corp/
or
• https://youtu.be/dWN3i6-Z9So
During the interview, Mr. Moscato spoke about the mission of Generex to create a new healthcare enterprise that delivers end-to-end solutions for the benefit of doctors and patients.
“My entire focus is on building value for our shareholders through execution on our strategy at Generex. Moving into 2020, we are focused on some very exciting projects including the buildout of our diabetes focused MSO and Diabetes Research Center of Excellence in Arizona, the acquisition of ALTuCELL and their encapsulation of cellular therapy products, and the spin-out of NuGenerex immune-Oncology as a separate, publicly traded company. This is a new era for Generex, and we plan to continue our march toward the Nasdaq up-listing.”
• http://ceoroadshow.com/ceoroadshow-interview-...logy-corp/
or
• https://youtu.be/dWN3i6-Z9So
During the interview, Mr. Moscato spoke about the mission of Generex to create a new healthcare enterprise that delivers end-to-end solutions for the benefit of doctors and patients.
“My entire focus is on building value for our shareholders through execution on our strategy at Generex. Moving into 2020, we are focused on some very exciting projects including the buildout of our diabetes focused MSO and Diabetes Research Center of Excellence in Arizona, the acquisition of ALTuCELL and their encapsulation of cellular therapy products, and the spin-out of NuGenerex immune-Oncology as a separate, publicly traded company. This is a new era for Generex, and we plan to continue our march toward the Nasdaq up-listing.”
(0)
(0)